e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Airways disease comorbidities and general aspects
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently
A. Bodzenta-Lukaszyk, J. A. van Noord, W. G. Schröder-Babo, K. McAulay, T. McIver (Bialystok, Poland; Heerlen, Netherlands; Gelnhausen, Germany; Cambridge, United Kingdom)
Source:
Annual Congress 2011 - Airways disease comorbidities and general aspects
Session:
Airways disease comorbidities and general aspects
Session type:
Thematic Poster Session
Number:
4007
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Bodzenta-Lukaszyk, J. A. van Noord, W. G. Schröder-Babo, K. McAulay, T. McIver (Bialystok, Poland; Heerlen, Netherlands; Gelnhausen, Germany; Cambridge, United Kingdom). Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently. Eur Respir J 2011; 38: Suppl. 55, 4007
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Effect of treatment with mometasone furoate/formoterol combination on rescue medication use
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
The salmeterol/fluticasone propionate combination 50/100 μg
b.i.d
is effective as initial maintenance therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products
Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests
Year: 2012
Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept